{"product_id":"aflac-bcg-matrix","title":"Aflac Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eCurious about Aflac's strategic product portfolio? This glimpse into their BCG Matrix highlights how their offerings are positioned for growth and profitability.  Understand which products are fueling their success and which might need a closer look.\u003c\/p\u003e\n\u003cp\u003eReady to unlock the full picture? Purchase the complete Aflac BCG Matrix report to gain detailed quadrant placements, identify their Stars, Cash Cows, Dogs, and Question Marks, and receive actionable insights to guide your own strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCritical Illness and Cancer Insurance (Japan)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAflac Japan stands as the undisputed leader in cancer and medical insurance within Japan, boasting a commanding market share built on years of experience and strong brand trust.  This dominance positions it favorably within the BCG matrix.\u003c\/p\u003e\n\u003cp\u003eThe company is set to introduce a new cancer insurance product in the spring of 2025, with early feedback indicating promising results. This strategic move aims to further solidify its market leadership.\u003c\/p\u003e\n\u003cp\u003eThe critical illness insurance sector is experiencing robust expansion, with global market size expected to climb from $286.98 billion in 2024 to $330.36 billion in 2025. This substantial growth underscores the high-potential nature of this market segment for Aflac.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplemental Health Insurance (U.S.)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAflac's supplemental health insurance in the U.S. is a clear star in its portfolio. As the leading provider with a substantial 27% market share, Aflac is well-positioned within this expanding sector.\u003c\/p\u003e\n\u003cp\u003eThe U.S. supplemental health market is experiencing robust growth, with projections indicating an increase from USD 40.58 billion in 2025 to an estimated USD 66.45 billion by 2034. This impressive compound annual growth rate of 5.60% underscores the market's vitality and Aflac's strong presence within it.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNew Accident Insurance Product (U.S.)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAflac introduced its new individual Accident Insurance product in February 2025, enhancing coverage with benefits like mental health therapy and expanded preventive care. This launch directly targets a critical financial vulnerability, with a staggering 51% of American employees unable to cover a $1,000 unexpected medical expense out-of-pocket, highlighting a substantial market opportunity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGroup Life and Disability Products (U.S.)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAflac's Group Life and Disability products in the U.S. are showing strong performance, contributing significantly to the company's overall growth. In the first quarter of 2025, Aflac U.S. reported a 3.5% year-over-year increase in sales, with these group offerings playing a key role in this expansion. \u003c\/p\u003e\n\u003cp\u003eThe strategic push through Aflac Group is designed to broaden the company's footprint by empowering brokers to cater to larger employers. This initiative taps into a market segment with considerable growth potential, as more businesses seek comprehensive group benefit solutions. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eSales Growth:\u003c\/strong\u003e Aflac U.S. experienced a 3.5% year-over-year sales increase in Q1 2025, with group life and disability products being a key driver.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Expansion:\u003c\/strong\u003e Aflac Group's strategy to enable brokers to serve larger employers opens up significant new market opportunities.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrategic Focus:\u003c\/strong\u003e The emphasis on growing the group benefits market segment reflects a deliberate effort to capture a larger share in a sector with promising expansion prospects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTsumitasu Product (Japan)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAflac Japan's Tsumitasu product is a key driver of its recent success, contributing to a 12.6% year-over-year sales increase in Q1 2025.\u003c\/p\u003e\n\u003cp\u003eThis product is strategically positioned to address both the accumulating wealth for retirement and the ongoing coverage needs after retirement, making it a comprehensive solution.\u003c\/p\u003e\n\u003cp\u003eIts particular success in attracting younger customers is a significant advantage in Japan's aging demographic landscape.\u003c\/p\u003e\n\u003cp\u003eThis focus on younger demographics signals a forward-thinking, high-growth strategy aimed at securing future market leadership for Aflac in Japan.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eProduct Focus:\u003c\/strong\u003e Tsumitasu addresses both retirement asset formation and post-retirement coverage.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSales Growth:\u003c\/strong\u003e Contributed to a 12.6% year-over-year sales increase for Aflac Japan in Q1 2025.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDemographic Appeal:\u003c\/strong\u003e Highly effective in acquiring younger customers.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrategic Importance:\u003c\/strong\u003e Targets younger demographics in an aging market for future growth.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAflac's Market Dominance: Supplemental Health \u0026amp; Group Life\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAflac's U.S. supplemental health insurance and its Group Life and Disability products in the U.S. are strong contenders for Star status. The U.S. supplemental health market is projected to grow from $40.58 billion in 2025 to $66.45 billion by 2034, with Aflac holding a significant 27% market share. Furthermore, Aflac U.S. saw a 3.5% year-over-year sales increase in Q1 2025, partly driven by its group offerings, which are expanding through a strategy to serve larger employers.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct Segment\u003c\/td\u003e\n\u003ctd\u003eMarket Share (U.S. Supplemental Health)\u003c\/td\u003e\n\u003ctd\u003eProjected Market Growth (U.S. Supplemental Health)\u003c\/td\u003e\n\u003ctd\u003eQ1 2025 Sales Growth (Aflac U.S.)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. Supplemental Health\u003c\/td\u003e\n\u003ctd\u003e27%\u003c\/td\u003e\n\u003ctd\u003e$40.58B (2025) to $66.45B (2034)\u003c\/td\u003e\n\u003ctd\u003eN\/A (driven by overall U.S. growth)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. Group Life \u0026amp; Disability\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eKey driver of 3.5% YoY growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eThe Aflac BCG Matrix provides a strategic overview of its business units, categorizing them as Stars, Cash Cows, Question Marks, or Dogs.\u003c\/p\u003e\n\u003cp\u003eThis analysis helps Aflac allocate resources effectively, identifying which units to invest in, hold, or divest for optimal portfolio performance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eAflac's BCG Matrix offers a clear, one-page overview of its business units, simplifying complex portfolio analysis for swift decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAflac Japan's Established Insurance Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAflac Japan's established insurance portfolio is a definitive cash cow for the company. This segment is the bedrock of Aflac's financial strength, contributing roughly 70% of its pretax adjusted earnings and holding a substantial 77% of total assets as of recent reporting periods. \u003c\/p\u003e\n\u003cp\u003eThe high premium persistency rate observed in Aflac Japan underscores its robust customer loyalty and the enduring value proposition of its offerings. This indicates that policyholders are consistently renewing their coverage, a clear sign of a stable and reliable revenue stream. \u003c\/p\u003e\n\u003cp\u003eDespite market dynamics, Aflac Japan continues to hold its position as the leading provider of cancer and medical insurance policies in force within Japan. This market leadership, coupled with consistent customer retention, ensures this segment remains a significant and dependable generator of substantial cash flow for the entire Aflac organization. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAflac U.S. Core Supplemental Offerings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAflac's U.S. core supplemental offerings, encompassing critical care, cancer, accident, disability, and hospital indemnity insurance, are firmly positioned as cash cows within the company's BCG matrix. These products benefit from stable persistency rates, consistently contributing to Aflac's adjusted earnings. For instance, Aflac reported that its U.S. segment's adjusted earnings per diluted share were $1.45 in the first quarter of 2024, with supplemental insurance playing a significant role in this performance.\u003c\/p\u003e\n\u003cp\u003eOperating in a mature market where Aflac enjoys a leading position, these established offerings generate reliable and predictable cash flow. The mature nature of these markets means lower promotional investments are required to maintain market share and sales volume. This allows Aflac to leverage its strong brand recognition and distribution channels effectively, ensuring sustained profitability from these core products.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDividend Payouts and Share Repurchases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAflac's commitment to shareholder returns is evident in its impressive 42-year streak of consistent dividend growth. This dedication is further underscored by the 16% increase in its first-quarter 2025 dividend to $0.58 per share, signaling strong confidence in future cash flows.\u003c\/p\u003e\n\u003cp\u003eIn 2024, Aflac returned a substantial $3.9 billion to its shareholders through a combination of dividends and share repurchases. This significant capital return directly reflects the robust and consistent cash generation capabilities of its established business lines, positioning them as true cash cows.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Distribution Channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAflac's established distribution channels, particularly its strong presence in the U.S. worksite market and its extensive network in Japan, are key to its Cash Cow status. These mature channels generate consistent premium income with relatively low investment needs, leading to healthy profit margins.\u003c\/p\u003e\n\u003cp\u003eIn 2023, Aflac reported U.S. segment total revenues of $12.9 billion, a testament to the enduring strength of its worksite distribution. Similarly, its Japan segment contributed significantly, with total revenues of $15.3 billion for the same period, highlighting the deep penetration and loyalty within its Japanese sales agent and business partner network.\u003c\/p\u003e\n\u003cp\u003eThe efficiency of these established channels allows Aflac to capitalize on its market position:\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eWorksite Dominance:\u003c\/strong\u003e Aflac's U.S. distribution focuses on offering supplemental insurance at the point of employment, a strategy that has proven highly effective and cost-efficient.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eJapanese Market Depth:\u003c\/strong\u003e In Japan, Aflac leverages a vast network of agents and business partners to reach a broad customer base for its life and cancer insurance products.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReduced Investment Needs:\u003c\/strong\u003e Unlike businesses in the question mark or star categories, Cash Cows like Aflac's distribution channels require minimal new investment for growth, freeing up capital.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHigh Profitability:\u003c\/strong\u003e The combination of consistent sales volume and lower operational costs translates into substantial and reliable profits for Aflac.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInvestment Portfolio Income\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAflac's investment portfolio functions as a robust cash cow, generating consistent income that underpins its financial strength and ability to meet policyholder obligations. This strategic asset allocation is designed for enduring performance, even when short-term market fluctuations, like the net investment losses impacting GAAP earnings in Q1 2025, create temporary headwinds.\u003c\/p\u003e\n\u003cp\u003eThe adjusted net investment income in Aflac U.S. demonstrated resilience, remaining stable. This consistent inflow of cash from investments is crucial for Aflac's operational stability and its capacity to pay claims and expenses, acting as a reliable source of funds.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eStable Adjusted Net Investment Income:\u003c\/strong\u003e Aflac U.S. reported stable adjusted net investment income, a key indicator of its reliable cash flow generation.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLong-Term Performance Focus:\u003c\/strong\u003e The investment portfolio is actively managed with a view towards long-term capital appreciation and income generation, ensuring sustained cash inflows.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFinancial Stability Pillar:\u003c\/strong\u003e The income generated from these investments provides essential financial backing, supporting policyholder promises and contributing significantly to Aflac's overall financial health.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplemental Insurance: Aflac's Cash Cow Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAflac's U.S. core supplemental insurance products, including critical care, cancer, accident, disability, and hospital indemnity, are firmly established as cash cows. These offerings benefit from stable persistency rates and consistently contribute to Aflac's adjusted earnings, with the U.S. segment reporting adjusted earnings per diluted share of $1.45 in Q1 2024.\u003c\/p\u003e\n\u003cp\u003eOperating in mature markets where Aflac holds a leading position, these products generate reliable cash flow with minimal need for increased promotional investments, leveraging strong brand recognition and distribution channels for sustained profitability.\u003c\/p\u003e\n\u003cp\u003eThe company's impressive 42-year track record of consistent dividend growth, including a 16% increase to $0.58 per share in Q1 2025, directly reflects the robust cash generation from these cash cow segments.\u003c\/p\u003e\n\u003cp\u003eIn 2024, Aflac returned $3.9 billion to shareholders via dividends and share repurchases, a clear indicator of the strong and consistent cash-generating power of its established business lines.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Shown\u003c\/span\u003e\u003cbr\u003eAflac BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe BCG Matrix analysis you are currently previewing is the identical, fully comprehensive document you will receive immediately after completing your purchase. This includes all detailed breakdowns and strategic insights, with no watermarks or demo content, ensuring you get a polished, ready-to-deploy strategic tool.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":55610902970745,"sku":"aflac-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/aflac-bcg-matrix.png?v=1754748375","url":"https:\/\/growthsharematrix.com\/products\/aflac-bcg-matrix","provider":"Growth Share Matrix","version":"1.0","type":"link"}